论文部分内容阅读
目的观察美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的临床效果。方法选取住院进行治疗的溃疡性结肠炎患者86例,按照临床治疗方式分为观察组46例和对照组40例。对照组给予口服美沙拉嗪进行治疗,观察组在对照组患者的治疗基础上,再给予口服双歧三联活菌胶囊进行治疗。结果经8周时间的临床治疗之后,观察组总有效率为93.48%显著高于对照组的72.50%,差异具有统计学意义(P<0.05)。观察组治疗后的临床症状评分、肠炎活动指数(DAI)评分和内镜评分下降的幅度显著大于对照组,差异具有统计学意义(P<0.05)。结论沙拉嗪联合双歧三联活菌片治疗溃疡性结肠炎于单独使用美沙拉嗪进行治疗相比,能够显著的提高患者临床治疗有效率,同时能显著的改善患者的临床症状,降低患者的DAI评分和内镜评分。
Objective To observe the clinical efficacy of mesalazine combined with bifidobacterium triple therapy in the treatment of ulcerative colitis. Methods Eighty-six patients with ulcerative colitis treated in hospital were divided into observation group (46 cases) and control group (40 cases). The control group was given oral mesalazine for treatment. The observation group was treated with oral bifid triple viable capsule on the basis of the treatment of patients in the control group. Results After 8 weeks’ clinical treatment, the total effective rate in the observation group was 93.48%, which was significantly higher than that in the control group (72.50%), the difference was statistically significant (P <0.05). Clinical symptom score, the index of inflammatory activity index (DAI) and the endoscopic score decreased significantly in observation group after treatment (P <0.05). CONCLUSIONS: Compared with the treatment of ulcerative colitis with mesalazine alone, the combination of clazapine and bifidobacterium triple viable can significantly improve the clinical efficiency of patients and significantly improve the clinical symptoms and reduce the DAI Score and endoscopic score.